Read an Excerpt
Overlooked Causes and the PreventionCancer, Cardiovascular Heart Disease, Multiple Sclerosis
By Arthur Douglass Alexander III
AuthorHouseCopyright © 2010 Arthur Douglass Alexander III
All right reserved.
Chapter OneThe Role of Certain Mycobacteria in Causing Cancer
Cancer reaches into every family around the world; it spares no one. In the United States today more than 1,400 persons die of this dreaded disease every day ... over 500,000 a year, with over 1,600,000 newly diagnosed with cancer each year. It is an epidemic! The accepted, conventional treatments of surgery, radiation and chemo- therapy offer no real assurance of cure, and the financial burdens these place on the patients, their families and the insurance companies are staggering - hundreds of billions of dollars per year. These medical costs are gradually bankrupting the country.
Thousands of dedicated researchers and clinicians are devoting their lives to the conquest and eradication of human cancer. Unfortunately, much of this money and these efforts are focussed on seeking new drugs and agents that will kill cancer; not on trying to discover or understand the fundamental causes or mechanisms underlying cancer. A primary reason for this is the premise that a chemical or biological "magic bullet" can be found that will magically destroy and cure cancer just as Fleming's discovery of penicillin prior to the second World War successfully healed most bacterial infections. If a chemotherapeutic agent temporarily kills some cancer cells, but does not cure the cancer, the patient will eventally die. Whereas, if medical research could discover the true underlying cause(s) of human cancer, the second most deadly health scourge in our lives next to heart disease could be cured or eliminated.
The Immune System and Cancer
Our body's first and best line of defense against disease is its own immune system. Cancer cells are characterised as the uncontrolled growth of our own mutant cells which escape immune surveillance and invade healthy tissues. Many researchers now believe that cancer growth closely parallels fetal growth within the mother's womb. In addition to extremely rapid cell division - common to cancer and fetal development - cancer cells share the same mechanism by which an embryo resists attack by its mother's immune system. Fetal cells produce the human growth hormone, human chorionic gonadotropin (HCG).
HCG, the first hormone produced in large quantities by the developing fetus, coats the surface of the fetal cells and shuts down attack by the mother's immune system. Cancer cells have been shown to also produce HCG, shielding them from recognition and attack and allowing them to grow and replicate in the body without stimulating an immunological response. A number of scientists now believe that a therapy that attacks and destroys HCG represents a potential key for successfully treating cancer.
Cancer has a number of contributing causes including bacterial, environmental exposure to toxins and carcinogens, stress weakening the natural immune system, nutritional deficiencies and excesses, as well as genetic and hereditary predisposition.
Largely overlooked and frequently ignored are the fundamental roles of bacteria and mycobacteria as a root cause of cancer.
Mycobacteria as an Underlying Root Cause of all Human Cancers
The late Dr. Virginia Livingston, M.D. (1906-1990) discovered and isolated a mycobacterium that is a primary cause of all human and animal cancers (a mycobacterium is a genus of rod-shaped acid-fast bacteria some of which cause Leprosy and Tuberculosis). To confirm that this isolated mycobacterium was indeed the root cause of cancer, she followed Koch's Postulate by injecting the mycobacteria into healthy animals that subsequently developed the same cancer as the donor in every case. She further demonstrated through brilliant research and clinical findings how this mycobacterium produces the many different forms of cancer and how it shields and protects itself from recognition and destruction by the natural human immune system.
Koch's Postulate: Nobel Prize recipient Robert Koch isolated and identified the Anthrax bacteria in 1876 and the Tubercular mycobacterium in 1883. In each case to prove that these bacteria caused the disease, Dr. Koch established the following criteria to satisfy his Postulate: That a single organism could be isolated and identified in every case of the disease; that the organism could be grown in vitro in pure culture; that the cultured organism would cause the disease when injected into healthy disease-free animals; and lastly, the organism could again be isolated and recovered from these now infected experimental animals.
Over the past 50 years, since her discovery of the cancer-causing mycobacterium, prominent research has established links between certain bacterial and viral infections, inflammation and most common cancers. Many investigators have reported the discovery of certain bacterial isolates from human and animal cancer tissue, as well as from the blood and urine of cancer patients.
Extensive evidence clearly linking this mycobacterium to cancer, was documented by Dr. Virginia Livingston (who defined it as the Progenitor cryptocides (PC) mycobacterium), Alexander Jackson, et.al., and published in the prestigious American Journal of Medicine Sciences in December 1950. Later confirmatory studies were published in the Annals and Transactions of the New York Academy of Sciences in 1970, 1972 and 1974. Despite this convincing research, bacterial organisms have been generally ignored as a potential cause of cancer. The reason for this may lie in the evasive nature of the pleomorphic PC mycobacterium. It is a master of disguise, taking on many different forms in the course of its growth and replication cycles. (See Figures 1 & 2)
Dr. Livingston profoundly stated that all reproductive life, whether of the fetus or the cancer cell, is controlled by Human Chorionic Gonadotropin (HCG). "It is the hormone of life" (shielding the fetus containing the foreign male's sperm cells from destruction by the mother's immune system), and "the hormone of death" (shielding the cancer cells from detection and destruction by the cancer patient's immune system.) Her findings have been confirmed by numerous investigators worldwide, including Drs. Acevedo and Slifkin in 1976 at the Department of Laboratory Medicine of Allegheny General Hospital in Pittsburgh.
By demonstrating that all cancer cells possess PC mycobacteria and that these mycobacteria produce HCG, Dr. Livingston showed that the HCG growth hormone shields and protects these cancer cells from recognition and attack by the body's immune system. The fact that most normal cells do not produce HCG suggests that an anti-HCG immunotherapy may offer a very specific means of treating cancer. This therapy would enable the immune system to overcome the barricade shielding the cancer cell. A number of scientists have come to believe that HCG represents an important clue for successfully treating cancer.
Because the PC mycobacterium in one of its many forms looks like a plant fungus, Dr. Livingston reasoned that a botanical substance might block its growth and replication. She discovered that CIS-14 (abscisic acid, a plant hormone called dormin) is a retinoid or Vitamin A analog that produces dormancy in seeds and plays a major regulatory role in the production of HCG by the PC microbe and the cancer cell. Cis-14 both blocks and deshields the HCG produced by the PC mycobacteria and the cancer cell. In turn, this allows immune system antibodies formed in response to the Immune Antigen (IA) vaccine to control and destroy both the PC mycobacteria and cancer cells.
She further discovered that the PC mycobacterium was closely related to the Tuberculin (TB) mycobacterium, and that a vaccine against one was cross-reactive to the other. Thus, Bacillus Calmette-Guerin (BCG) - a weakened live tubercular vaccine used to stimulate the human immune system's production of specific antibodies against Tuberculosis - was also an effective vaccine against human cancer.
Livingston Patient Outcome Survey Report
A survey study was conducted during October 2002 to determine how well the current cancer patient population at the Livingston Foundation Medical Center (LFMC) fared in terms of survival and quality of life. The patients were treated only with non-toxic immunotherapy to restore and enhance their immune systems to effectively fight against their serious chronic disease.
Of 532 patients treated and re-evaluated at LFMC in San Diego during the period 1999 through October 2002, 260 had been on Livingston immunotherapy for less than two years; 118 had been on the LFMC program for two to five years; and 126 patients had been on the program for more than five years (some for over 25 years) and are doing well. Their cancers have remained in remission and their quality of life has continued to be good.
Of the 324 patients with Breast, Prostate, Melanoma, Ovarian and Lymphoma Cancer (see Table 1 below), the Livingston immunotherapy program appeared to be particularly successful in restoring the immune system of these patients. In addition, the remaining 208 patients, representing 40 other types of cancer, also did well on LFMC immunotherapy; however, the number of patients in each cancer classification was statistically insignificant to allow them to be included in this limited survey study.
Despite the fact that many of these patients had been treated with surgery, radiation and/or chemotherapy before coming to LFMC with late-stage cancers, this survey indicated that Livingston non-toxic immunotherapy survival times and quality of life exceeded the so-called "five year survival" standard adopted by conventional medicine.
Chapter TwoThe Role of Specific Vaccines in the Treatment of Cancer
In 1973, Dr. Livingston learned about the amazing success Dr. Chisato Maruyama, M.D. (head of the Research Institute of Vaccine Therapy for Tumors and Infectious Diseases at the Nippon Medical School, Tokyo, Japan) had in treating both Leprosy and Cancer with Bacillus Calmette-Guerin (BCG). Dr. Maruyama used the BCG vaccine to effectively treat Leprosy (a relative of tuberculosis), and 871 cases of cancer of the lung, esophagas, stomach, intestine, liver, pancreas, uterus, ovary, etc. It proved very effective in 144 cases, exhibiting some effect in 271 cases, and little or no effect in the remaining 316 cases.
Dr. Livingston also learned that Dr. Maruyama had increased the strength of his BCG vaccine by almost 1,000 fold by stripping the protein sheath surrounding the active BCG DNA, which then proved far more viable. Armed with this knowledge, she asked her biochemical associate, Dr. John J. Majnarich, PhD, to strip the protein sheath from a patient's autogenous (self-) PC mycobacterium to produce a universal anti-cancer vaccine that could be widely used in treating all patients' cancers - thus, the Purified Antigen (PA) vaccine was created.
The PC Immune Antigen (IA) Autogenous Vaccine
The Immune Antigen (IA) is a specific antigen made from each individual cancer patient's strain of the Progenitor cryptocides (PC) mycobacterium. It is used to stimulate and enhance the immune system's ability to produce specific antibodies against the disease-causing PC. The IA is the keystone in stimulating the cancer patient's immune system's ability to control and destroy the invasive PC, the primary root cause of most human cancers.
The PC Purified Antigen (PA) Vaccine
The Purified Antigen residue fractions are prepared from a PC culture producing chorionic gonadotropin. The PA consists of the cell wall components and associated proteins and glycoproteins of a chorionic gonadotropin (HCG) producing organism isolated from human tumor tissue. By stripping the protein sheath from the mycobacterium DNA, the Purified Antigen became a universal vaccine, rather than an autogenous vaccine exclusively for the original donor. It could now be used as a universal vaccine against any patients' cancer. Antigens prepared from the PC mycobacterium activate and stimulate the patient's specific immune response to the cancer-causing mycobacteria. This effect was demonstrated extensively against a spectrum of laboratory animal tumors (see Figure 2).
Subsequent clinical trials, though limited in scope, provided strong evidence that the PA extract produced a significant response to many different neoplastic diseases and severe immuno deficiencies such as AIDS (see Figure 3).
The e[??] Factor Vaccine
The [e.sup.+]Factor is a non-toxic synthetic seven amino acid peptide developed by Dr. John J. Majnarich for the Livingston Foundation Medical Center. Alone, the [e.sup.+]Factor elicits a strong antigen-specific immune T-lymphocyte activity against systemic PC mycobacteria and cancer cells. In combination with the Immune Antigen or the Purified Antigen, it stimulates and exhibits strong anti-cancer activity (anti-angiogenesis).
In preclinical trials against Sarcoma 180 tumors in white mice, the [e.sup.+]Factor produced 77.3% inhibition of the tumors. When added to the Immune Antigen (IA), the combination vaccine of IA and the [e.sup.+]Factor produced 76.6% inhibition of the tumors, whereas the Immune Antigen (IA) vaccine alone only produced 44.6% inhibition of the Sarcoma 180.
The Custom Formula Vaccine
The Custom Formula is a splenic, thymus and liver extract from disease-free sheep used to stimulate white blood cell (WBC) production in the bone marrow of cancer patients. Often, after extensive cancer treatment, the patient's white count is extremely low, thus compromising the immune system's ability to mobilize immune cells and attack and destroy invading disease-causing bacteria and mycobacteria.
The Role of Certain Carcinogens and Viruses in Causing Cancers
Pesticides and Breast Cancer
The New York Times carried a front page article that states that two of the leading agricultural insecticides extensively used in the United States had been clearly linked to breast cancer. These were produced*1 by Imperial Chemicals (ICI) of Great Britain and its subsidiary, Astra Zeneca. "Ironically, the United States Breast Cancer Month was founded and sponsored by Zeneca Chemicals (a subsidiary of ICI) which earns millions from the sales of carcinogenic pesticides, and now, as Astra Zeneca, from the breast cancer drug, Tamoxifen.. Zeneca also purchased the largest for-profit cancer treatment centers in the United States, Salick Health Care Inc., neatly assuring profits both from causing and curing breast cancer. Among a few of the many pesticides that increase the risk of breast cancer are: lindane, permethrin, cypermethrin, and captan.
"Most of the pesticides implicated in breast cancer are still in common use because of regulatory failure to update scientific research; instead, regulators rely on toxicological data suppied by the pesticide manufacturers as 'proof' that a pesticide is 'acceptable'."
"Breast cancer incidence rates in the United States rose by 24% between 1973 and 1991. Breast cancer risk factors may vary by birth cohort, including age at menarche, age at first birth, physical activity, obesity, diet, alcohol intake, estrogen therapy and exposure to environmental organochlorines (pesticides).
H. pylori (Helicobacter pylori) - a Bacterial Cause of Cancer
H. pylori (Helicobacter pylori) bacteria infects over half the world's population. Ordinarily it causes no symptoms; however, it can lead to serious complications such as gastric ulcers and cancer. H. Pylori is primarily passed from person to person through direct contact with saliva or fecal matter. Well adapted to the stomach's acid environment, it produces an enzyme creating a low-acid buffer zone. If untreated, H. Pylori can cause gastric cancer.
Excerpted from Overlooked Causes and the Prevention by Arthur Douglass Alexander III Copyright © 2010 by Arthur Douglass Alexander III. Excerpted by permission.
All rights reserved. No part of this excerpt may be reproduced or reprinted without permission in writing from the publisher.
Excerpts are provided by Dial-A-Book Inc. solely for the personal use of visitors to this web site.